Recognising and managing adverse events

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

A guide to help manage and address common LENVIMA® (lenvatinib)-induced adverse events (AEs) as early and effectively as possible. This guide has been developed based on the KEYTRUDA® (pembrolizumab) and LENVIMA SmPC, supplemented with additional guidelines and recommendations for managing AEs where appropriate.

KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting, and who are not candidates for curative surgery or radiation.1

Please consult the SmPC for further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.

More information about KEYTRUDA® (pembrolizumab) in endometrial cancer


  1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website